Catalog No.S1713 Synonyms: CP 16171
Molecular Weight(MW): 331.35
Piroxicam is a non-selective COX inhibitor, used in the treatment of rheumatoid and osteoarthritis.
Purity & Quality Control
Choose Selective COX Inhibitors
|Description||Piroxicam is a non-selective COX inhibitor, used in the treatment of rheumatoid and osteoarthritis.|
Piroxicam induces activation of extracellular signal-regulated kinase (ERK) in neurones and phosphorylation of heavy molecular weight neurofilaments, cytoskeletal substrates of ERK in rat spinal cord cultures. Piroxicam and NS-398 protect neurones against hypoxia/reperfusion in rat spinal cord cultures. 
|In vivo||Piroxicam at doses higher than 0.04%, strongly inhibits the development of GST-P-positive and neoplastic nodules as well as fibrosis, cirrhosis and formation of 8-hydroxydeoxyguanosine (8-OHdG) adducts in rats.  Piroxicam increases the expression of all three MHC antigens compared to either control or azoxymethane (AOM)-treated rats. Piroxicam up-regulates colonic MHC antigen expression in the AOM model of colonic carcinogenesis.  Piroxicam combined with Cisplatin has antitumor activity against oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC) in rats.  Piroxicam inhibits prostaglandin synthesis through cyclooxygenase blockade in dog, and Piroxicam does not have any direct cytotoxic effects in vitro.  Piroxicam also binds strongly to plasma proteins and Piroxicam could stop Ochratoxin A (OTA) -binding and transport into target organs, thereby preventing its nephrotoxicity in rats. Piroxicam prevents the enzymuria induced by OTA and increases renal elimination of OTA in rats. |
-  Vartiainen N, et al. J Neurochem,?001, 76(2), 480-489.
-  Denda A, et al. Carcinogenesis,?997, 18(10), 1921-1930.
-  Rigas B, et al. Immunology,?994, 83(2), 319-323.
|In vitro||DMSO||66 mg/mL (199.18 mM)|
|Ethanol||1 mg/mL (3.01 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03006107||Not yet recruiting||Pulpitis - Irreversible||Cairo University||December 2016||--|
|NCT02304783||Recruiting||Renal Colic||University of Monastir||January 2014||Phase 1|Phase 2|
|NCT02253446||Completed||Primary Dysmenorrhea||Pamukkale University||May 2013||Phase 4|
|NCT02450487||Completed||Pain|Other Surgical Procedures|Impacted Third Molar Tooth|Cytochrome P450 CYP2C9 Enzyme Deficiency||University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo||October 2012||Phase 4|
|NCT01320709||Completed||Contraception, Postcoital||Bayer||March 2011||Phase 2|
|NCT00670475||Completed||Osteoarthritis of the Knee||Ardabil University of Medical Sciences||April 2008||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.